Trastuzumab

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab (coding:ncit:C1647)

RxNorm: trastuzumab (coding:rxcui:224905, coding:omop:4304158)

SNOMED: Trastuzumab (coding:sctid:387003001, coding:omop:1387104)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations	Biomarkers	Cancer types	Therapies
FDA (1) HC (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (2) HC (5)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) HC (2)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
FDA (1)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab
FDA (1) HC (1)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib
HC (1)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
HC (2)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (2)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
HC (2)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
HC (1)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Paclitaxel, Trastuzumab
FDA (1)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib